NeM0ooo
2021-11-20
Like
Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review<blockquote>百时美施贵宝股价因FDA心脏药物审查而持续下滑</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":872041487,"tweetId":"872041487","gmtCreate":1637380791968,"gmtModify":1637380792157,"author":{"id":4091976027440070,"idStr":"4091976027440070","authorId":4091976027440070,"authorIdStr":"4091976027440070","name":"NeM0ooo","avatar":"https://static.tigerbbs.com/fc945b6e362666c4cb11d3c9b09018e8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/872041487","repostId":1111549440,"repostType":4,"repost":{"id":"1111549440","kind":"news","pubTimestamp":1637372002,"share":"https://www.laohu8.com/m/news/1111549440?lang=zh_CN&edition=full","pubTime":"2021-11-20 09:33","market":"us","language":"en","title":"Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review<blockquote>百时美施贵宝股价因FDA心脏药物审查而持续下滑</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111549440","media":"The Street","summary":"$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has exte","content":"<p>$Bristol Myers Squibb (<b>BMY</b>)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.</p><p><blockquote>$百时美施贵宝(<b>BMY</b>)$股价周五下跌，此前这家制药巨头表示FDA已将心脏药物mavacamten的审查延长三个月，直至4月28日。</blockquote></p><p> The drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).</p><p><blockquote>该药物治疗症状性梗阻性肥厚型心肌病（oHCM）。</blockquote></p><p> The Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.</p><p><blockquote>该公司表示，美国食品和药物管理局周四通知布里斯托尔延期，“以便有足够的时间审查与拟议风险评估缓解策略（REMS）更新相关的信息”。</blockquote></p><p> “A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”</p><p><blockquote>“mavacamten的初始申请中包含了REMS计划。没有要求额外的数据或研究。”</blockquote></p><p> Bristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.</p><p><blockquote>百时美施贵宝近期交易价格为58.07美元，下跌1.6%。过去三个月下跌了14%。</blockquote></p><p> “We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.</p><p><blockquote>百时美施贵宝全球药物开发首席医疗官Samit Hirawat表示：“我们对mavacamten的前景充满信心。”</blockquote></p><p> “This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”</p><p><blockquote>“在关键的EXPLORER-HCM试验中，这种一流的心肌肌球蛋白抑制剂在有症状的oHCM患者的症状、功能状态和生活质量方面表现出了具有临床意义的改善。”</blockquote></p><p> Mavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.</p><p><blockquote>据MarketWatch报道，Mavacamten是MyoKardia最具潜力的药物，百时美施贵宝去年以131亿美元收购了该药物。</blockquote></p><p> Morningstar analyst Damien Conover puts fair value for Bristol Myers at $68.</p><p><blockquote>晨星分析师Damien Conover认为百时美施贵宝的公允价值为68美元。</blockquote></p><p> “Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.</p><p><blockquote>他在周二的评论中写道：“百时美施贵宝举办了投资者日活动，强调了强大的产品线，有可能抵消该公司未来十年的重大专利损失，这是支持我们宽护城河评级的关键因素。”</blockquote></p><p> “With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”</p><p><blockquote>“由于大多数更新都集中在仍然有风险的早期管道资产上，因此这些更新并没有改变我们的公允价值估计。然而，我们仍然认为该股被低估，因为市场没有完全欣赏该公司的后期管道。”</blockquote></p><p></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Stock Keeps Skidding on FDA Heart Drug Review<blockquote>百时美施贵宝股价因FDA心脏药物审查而持续下滑</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Stock Keeps Skidding on FDA Heart Drug Review<blockquote>百时美施贵宝股价因FDA心脏药物审查而持续下滑</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Street</strong><span class=\"h-time small\">2021-11-20 09:33</span>\n</p>\n</h4>\n</header>\n<article>\n<p>$Bristol Myers Squibb (<b>BMY</b>)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.</p><p><blockquote>$百时美施贵宝(<b>BMY</b>)$股价周五下跌，此前这家制药巨头表示FDA已将心脏药物mavacamten的审查延长三个月，直至4月28日。</blockquote></p><p> The drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).</p><p><blockquote>该药物治疗症状性梗阻性肥厚型心肌病（oHCM）。</blockquote></p><p> The Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.</p><p><blockquote>该公司表示，美国食品和药物管理局周四通知布里斯托尔延期，“以便有足够的时间审查与拟议风险评估缓解策略（REMS）更新相关的信息”。</blockquote></p><p> “A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”</p><p><blockquote>“mavacamten的初始申请中包含了REMS计划。没有要求额外的数据或研究。”</blockquote></p><p> Bristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.</p><p><blockquote>百时美施贵宝近期交易价格为58.07美元，下跌1.6%。过去三个月下跌了14%。</blockquote></p><p> “We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.</p><p><blockquote>百时美施贵宝全球药物开发首席医疗官Samit Hirawat表示：“我们对mavacamten的前景充满信心。”</blockquote></p><p> “This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”</p><p><blockquote>“在关键的EXPLORER-HCM试验中，这种一流的心肌肌球蛋白抑制剂在有症状的oHCM患者的症状、功能状态和生活质量方面表现出了具有临床意义的改善。”</blockquote></p><p> Mavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.</p><p><blockquote>据MarketWatch报道，Mavacamten是MyoKardia最具潜力的药物，百时美施贵宝去年以131亿美元收购了该药物。</blockquote></p><p> Morningstar analyst Damien Conover puts fair value for Bristol Myers at $68.</p><p><blockquote>晨星分析师Damien Conover认为百时美施贵宝的公允价值为68美元。</blockquote></p><p> “Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.</p><p><blockquote>他在周二的评论中写道：“百时美施贵宝举办了投资者日活动，强调了强大的产品线，有可能抵消该公司未来十年的重大专利损失，这是支持我们宽护城河评级的关键因素。”</blockquote></p><p> “With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”</p><p><blockquote>“由于大多数更新都集中在仍然有风险的早期管道资产上，因此这些更新并没有改变我们的公允价值估计。然而，我们仍然认为该股被低估，因为市场没有完全欣赏该公司的后期管道。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review\">The Street</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝"},"source_url":"https://www.thestreet.com/investing/bristol-myers-heart-drug-mavacamten-gets-extended-fda-review","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111549440","content_text":"$Bristol Myers Squibb (BMY)$ shares fell Friday after the pharmaceutical titan said the FDA has extended its review of heart drug mavacamten for three months, until April 28.\nThe drug treats symptomatic obstructive hypertrophic cardiomyopathy (oHCM).\nThe Food and Drug Administration notified Bristol Thursday of the extension “to allow sufficient time to review information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS),” the company said.\n“A REMS program was included in the initial application for mavacamten. No additional data or studies have been requested.”\nBristol Myers recently traded at $58.07, down 1.6%. It has slid 14% over the past three months.\n“We are confident in the profile of mavacamten,” said Samit Hirawat, chief medical officer, global drug development at Bristol Myers.\n“This first-in-class cardiac myosin inhibitor demonstrated clinically meaningful improvements in symptoms, functional status, and quality of life in symptomatic oHCM patients in the pivotal EXPLORER-HCM trial.”\nMavacamten represented the top potential drug of MyoKardia, which Bristol Myers acquired last year for $13.1 billion, MarketWatch reports.\nMorningstar analyst Damien Conover puts fair value for Bristol Myers at $68.\n“Bristol Myers hosted an investor day highlighting a strong pipeline that holds the potential to offset the firm’s major patent losses over the next decade, a key element supporting our wide moat rating,” he wrote in a commentary Tuesday.\n“With most of the updates focused on still risky early-stage pipeline assets, the updates didn’t move our fair value estimate. However, we continue to view the stock as undervalued with the market not fully appreciating the firm’s late-stage pipeline.”","news_type":1,"symbols_score_info":{"BMY":0.9}},"isVote":1,"tweetType":1,"viewCount":353,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/872041487"}
精彩评论